Patents by Inventor Mats Ander

Mats Ander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10501557
    Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52 wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO:4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: December 10, 2019
    Assignee: GE HEALTHCARE BIOPROCESS R&D AB
    Inventors: Gustav Rodrigo, Tomas Bjorkman, Mats Ander
  • Publication number: 20190263856
    Abstract: The present invention relates to the field of chromatography and more specifically to producing protein affinity chromatography resins comprising affinity ligands based on a N-terminal fragment of a split intein, such as DnaE from Nostoc punctiforme, as well as methods for using the same. The N-terminal fragments are produced in inclusion bodies in bacterial cells.
    Type: Application
    Filed: November 14, 2017
    Publication date: August 29, 2019
    Inventors: Johan Ohman, Mats Ander, Therese Graner, Anneli Jorsback, Jinyu Zou
  • Publication number: 20190212456
    Abstract: A method of operating a global positioning receiver is provided. The method includes receiving a plurality of signals from a plurality of satellites. At least a measurement from and location of each satellite is determined based on the received plurality of signals. An approximate vehicle velocity vector is determined based on the received plurality of signals. A dot product between a line of sight between each satellite and a vehicle having the receiver and the determined vehicle velocity vector is determined. Each measurement associated with each determined dot product that is below a minimum dot product threshold is removed to obtain a resultant set of measurements. A position solution based on the resultant set of measurements is then determined.
    Type: Application
    Filed: January 9, 2018
    Publication date: July 11, 2019
    Applicant: Honeywell International Inc.
    Inventors: Brian Schipper, Mats Anders Brenner, Martin Musil
  • Patent number: 10308690
    Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, comprising at least the mutation wherein the glutamine residue at position 9 has been mutated to a tryptophan, leucine, glutamic acid, valine or lysine. The invention also discloses multimers of the polypeptide, as well as separation matrices comprising the multimers or polypeptides.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: June 4, 2019
    Assignee: GE HEALTHCARE BIOPROCESS R&D AB
    Inventors: Gustav Rodrigo, Mats Ander, Göran Baurén, Tomas Björkman
  • Publication number: 20190144511
    Abstract: A kappa light chain-binding polypeptide comprising or consisting essentially of one or more mutated binding domains of Peptostreptococcus Protein L.
    Type: Application
    Filed: January 18, 2019
    Publication date: May 16, 2019
    Inventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman
  • Publication number: 20190144496
    Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52, wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO: 4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
    Type: Application
    Filed: May 10, 2017
    Publication date: May 16, 2019
    Inventors: Gustav José Rodrigo, Tomas Bjorkman, Mats Ander
  • Publication number: 20190119318
    Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.
    Type: Application
    Filed: May 10, 2017
    Publication date: April 25, 2019
    Inventors: Gustav José Rodrigo, Tomas Bjorkman, Mats Ander, Jesper Ulf Hansson
  • Patent number: 10215862
    Abstract: Systems and methods for a code carrier divergence (CCD) high-pass filter monitor are provided.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: February 26, 2019
    Assignee: Honeywell International Inc.
    Inventors: Justin Joseph Syrstad, Mats Anders Brenner, John M. Howard, Kim A. Class, Bruce G. Johnson, Randy J. Reuter
  • Patent number: 10208091
    Abstract: A kappa light chain-binding polypeptide comprising or consisting essentially of one or more binding domains of Peptostreptococcus Protein L, each of said domains being selected from the group consisting of domain 2, domain 3 and domain 4.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 19, 2019
    Assignee: GE HEALTHCARE BIOPROCESS R&D AB
    Inventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman
  • Patent number: 10208092
    Abstract: The invention discloses kappa light chain-binding polypeptide comprising a mutated binding domain of Peptostreptococcus protein L, wherein at least one asparagine residue of a parental domain defined by, or having at least 95% or 98% sequence homology with, SEQ ID NO: 2-6 or 2 has been mutated to another amino acid residue which is not asparagine, proline or cysteine.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: February 19, 2019
    Assignee: GE Healthcare Bio-Process R&D AB
    Inventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman
  • Patent number: 10189891
    Abstract: The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to H18 of the B domain of Protein A or of Protein Z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to H18 of the B domain of protein A or of protein Z is not serine, threonine or lysine.
    Type: Grant
    Filed: March 26, 2013
    Date of Patent: January 29, 2019
    Assignee: GE Healthcare BioProcess R&D AB
    Inventors: Mats Ander, Goran Bauren, Tomas Bjorkman, Per-Mikael Aberg, Gustav Rodrigo
  • Publication number: 20180327512
    Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO 26 or SEQ ID NO 27, wherein at least the alanine residue at the position corresponding to position 42 in SEQ ID NO:4-7 has been mutated to arginine and/or wherein at least the aspartic acid residue at the position corresponding to position 37 in SEQ ID NO:4-7 has been mutated to glutamic acid.
    Type: Application
    Filed: November 11, 2015
    Publication date: November 15, 2018
    Applicant: GE HEALTHCARE BIOPROCESS R&D AB
    Inventors: Gustav Rodrigo, Tomas Bjorkman, Mats Ander
  • Patent number: 10112980
    Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamic acid residue at position 15 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: October 30, 2018
    Assignee: GE HEALTHCARE BIOPROCESS R&D AB
    Inventors: Mats Ander, Goran Bauren, Tomas Bjorkman, Gustav Rodrigo
  • Publication number: 20180244729
    Abstract: The invention discloses a polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A (SpA), as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 9 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.
    Type: Application
    Filed: February 20, 2018
    Publication date: August 30, 2018
    Applicant: GE Healthcare BioProcess R&D AB
    Inventors: Gustav Rodrigo, Mats Ander, Tomas BJORKMAN, Goran Bauren
  • Patent number: 9964645
    Abstract: A method of implementing a real-time screening process for phase scintillation is presented. The method includes detecting a phase scintillation event during a sample time period at a phase scintillation monitor; excluding associated satellite measurement data from further use based on the detection of the phase scintillation event at the phase scintillation monitor; detecting an end to the phase scintillation event at the phase scintillation monitor; and readmitting associated satellite measurement data collected after the end of the phase scintillation event as detected by the phase scintillation monitor.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: May 8, 2018
    Assignee: Honeywell International Inc.
    Inventors: Joseph E. Scheitlin, Mats Anders Brenner, Kim A. Class, Bruce G. Johnson, Randy J. Reuter, John M. Howard
  • Publication number: 20180094024
    Abstract: The invention relates to a method of isolating an immunoglobulin, comprising the steps of: a) providing a separation matrix comprising multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, b) contacting a liquid sample comprising an immunoglobulin with the separation matrix, c) washing said separation matrix with a washing liquid, d) eluting the immunoglobulin from the separation matrix with an elution liquid, and e) cleaning the separation matrix with a cleaning liquid, wherein the alkali-stabilized Protein A domains comprise mutants of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by, or having at least 80% such as at least 90%, 95% or 98% identity to, SEQ ID NO 51 or SEQ ID NO 52, wherein the amino acid residues at positions 13 and 44 of SEQ ID NO 51 or 52 are asparagines and wherein at least the asparagine residue at position 3 of SEQ ID NO 51 or 52 has been mutated to an amino acid selected from the group consisti
    Type: Application
    Filed: November 10, 2016
    Publication date: April 5, 2018
    Inventors: Annika Kristina FORSS, Gustav Jose RODRIGO, Tomas BJORKMAN, Jesper Ulf Hansson, Mats Ander
  • Patent number: 9915734
    Abstract: Systems and methods for averaging satellite sigmas and readmitting excluded satellite measurements into differential corrections and integrity monitors are provided. In one embodiment, a method comprises: calculating a first RFI based averaged sigma and a second RFI based averaged sigma, wherein the first RFI based averaged sigma includes a sigma for the excluded satellite measurement and wherein the second RFI based averaged sigma does not include the sigma for the excluded satellite measurement; and, readmitting the excluded satellite measurement into either a differential correction broadcast or a respective integrity monitor when the first RFI based averaged sigma is less than or equal to the second RFI based averaged sigma.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: March 13, 2018
    Assignee: Honeywell International Inc.
    Inventors: Joseph E. Scheitlin, Mats Anders Brenner
  • Patent number: 9896486
    Abstract: A polypeptide with improved alkaline stability, which polypeptide comprises a mutant of a B or C domain of Staphylococcus Protein A, as specified by SEQ ID NO 1 or SEQ ID NO 2, or of Protein Z, as specified by SEQ ID NO 3, wherein at least the glutamine residue at position 9 has been mutated to an amino acid other than asparagine. The invention also discloses multimers of said polypeptide, as well as separation matrices comprising the multimers or polypeptides.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: February 20, 2018
    Assignee: GE Healthcare BioProcess R&D AB
    Inventors: Gustav Rodrigo, Mats Ander, Tomas Bjorkman, Goran Bauren
  • Publication number: 20180044374
    Abstract: The invention relates to a method of isolating an immunoglobulin, comprising the steps of: a) providing a separation matrix comprising at least 15 mg/ml multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, wherein the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml; b) contacting a liquid sample comprising an immunoglobulin with the separation matrix; c) washing the separation matrix with a washing liquid; d) eluting the immunoglobulin from the separation matrix with an elution liquid; and e) cleaning the separation matrix with a cleaning liquid comprising at least 0.5 M NaOH.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 15, 2018
    Inventors: Annika Forss, Mats Ander, Tomas Bjorkman, Hans Blom, Jesper Hansson, Gustav Rodrigo
  • Patent number: 9880021
    Abstract: Systems and methods for attitude fault detection in an inertial measurement unit (IMU) are disclosed. In one embodiment, an avionics system comprises: an IMU configured to produce a calculated pitch solution, a calculated roll solution, or both; a monitor coupled to the IMU and configured to produce an estimated pitch solution, an estimated roll solution, or both; a comparator, wherein the comparator determines the difference between the calculated pitch solution and the estimated pitch solution, the difference between the calculated roll solution and the estimated roll solution, or both; and a display device communicatively coupled to the comparator; wherein the display device receives a warning message from the comparator when the difference between the calculated pitch solution and the estimated pitch solution is greater than a pitch threshold, or when the difference between the calculated roll solution and the estimated roll solution is greater than a roll threshold, or both.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: January 30, 2018
    Assignee: Honeywell International Inc.
    Inventors: Mats Anders Brenner, John R. Morrison